Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines

Current Development and Challenges of Tetravalent Live-Attenuated Dengue Vaccines

Dengue is the most common arboviral disease caused by one of four distinct but closely related dengue viruses (DENV) and places significant economic and public health burdens in the endemic areas. A dengue vaccine will be important in advancing disease control. However, the effort has been challenge...

Full description

Bibliographic Details
Main Authors:	Hou, Jue, Ye, Weijian, Chen, Jianzhu
Other Authors:	Singapore-MIT Alliance in Research and Technology (SMART)
Format:	Article
Published:	Frontiers Media SA 2022
Online Access:	https://hdl.handle.net/1721.1/141032

Similar Items

Moving forward with Takeda's live chimeric tetravalent dengue vaccine
by: Wilder-Smith, Annelies
Published: (2017)

Long-term safety assessment of live attenuated tetravalent dengue vaccines: Deliberations from a WHO technical consultation
by: Bentsi-Enchill, A, et al.
Published: (2013)

Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation.
by: Bentsi-Enchill, A, et al.
Published: (2013)

Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine
by: Wilder-Smith, Annelies, et al.
Published: (2016)

Successive Immunization With Epitope-Decreasing Dengue Antigens Induced Conservative Anti-Dengue Immune Responses
by: Hou, Jue, et al.
Published: (2021)

Genetic epidemiology of dengue virus in phase III trials of the CYD tetravalent vaccine and implications for efficacy
by: Rabaa, MA, et al.
Published: (2017)

Current Developments and Challenges of mRNA Vaccines
by: Chen, Jinjin, et al.
Published: (2022)

Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines
by: Vannice, Kirsten S., et al.
Published: (2018)

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
by: Snape, MD, et al.
Published: (2008)

Dengue: Status of current and under‐development vaccines
by: Redoni, M, et al.
Published: (2020)

Development of live attenuated Enterovirus 71 vaccine strains that confer protection against lethal challenge in mice
by: Yee, Pinn Tsin Isabel, et al.
Published: (2019)

Dengue Mosaic Vaccines Enhance Cellular Immunity and Expand the Breadth of Neutralizing Antibody Against All Four Serotypes of Dengue Viruses in Mice
by: Hou, Jue, et al.
Published: (2020)

Dengue : challenges for policy makers and vaccine developers
by: Wilder-Smith, Annelies, et al.
Published: (2014)

Development of live attenuated fowl adenovirus isolate of Malaysia for vaccine production
by: Mohamed Sohaimi, Norfitriah
Published: (2017)

Proteomics as a tool for live attenuated influenza vaccine characterisation
by: Hawksworth, A, et al.
Published: (2019)

Use of fractional dose tetravalent A, C, W135 and Y meningococcal polysaccharide vaccine: A non inferiority trial
by: Guerin, P, et al.
Published: (2006)

What time interval is needed between the administration of live attenuated vaccines?
by: Zimmermann, P, et al.
Published: (2020)

The long-term safety, public health impact, and cost-effectiveness of routine vaccination with a recombinant, live-attenuated dengue vaccine (Dengvaxia): A model comparison study
by: Flasche, S, et al.
Published: (2016)

Sequential immunization induces strong and broad immunity against all four dengue virus serotypes.
by: Hou, Jue, et al.
Published: (2022)

Sequential immunization induces strong and broad immunity against all four dengue virus serotypes.
by: Hou, Jue, et al.
Published: (2021)

Product and process validation for cold chain free, live attenuated cholera vaccine
by: Chan Yean, Yean
Published: (2018)

Dengue Virus-Infected Dendritic Cells, but Not Monocytes, Activate Natural Killer Cells through a Contact-Dependent Mechanism Involving Adhesion Molecules
by: Costa, Vivian Vasconcelos, et al.
Published: (2017)

Dengue virus-infected dendritic cells, but not monocytes, activate natural killer cells through a contact-dependent mechanism involving adhesion molecules
by: Costa, Vivian Vasconcelos, et al.
Published: (2019)

Cellular immune responses to live attenuated Japanese Encephalitis (JE) vaccine SA14-14-2 in adults in a JE/dengue co-endemic area.
by: Turtle, L, et al.
Published: (2017)

Development of a recombinant genotype-matched live attenuated vaccine against genotype VII Newcastle disease virus
by: Bello, Muhammad Bashir
Published: (2018)

Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination? The challenges of a dengue vaccine
by: Screaton, G, et al.
Published: (2018)

Assessing dengue vaccination impact: Model challenges and future directions.
by: Recker, M, et al.
Published: (2016)

Development of Vibrio harveyi protease deletion mutant as live attenuated vaccine against vibriosis in Epinephelus fuscoguttatus (Forsskal, 1775)
by: Mohd Aris, Aslizah
Published: (2018)

Avidity of serogroup A meningococcal IgG antibodies after immunization with different doses of a tetravalent A/C/Y/W135 polysaccharide vaccine.
by: Bårnes, G, et al.
Published: (2011)

Serum Metabolomics Investigation of Humanized Mouse Model of Dengue Virus Infection
by: Cui, Liang, et al.
Published: (2018)

Mutating chikungunya virus non‐structural protein produces potent live‐attenuated vaccine candidate
by: Chan, Y, et al.
Published: (2019)

Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates.
by: Fan, S, et al.
Published: (2009)

Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine.
by: Nixon, D, et al.
Published: (2000)

Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial
by: Sharma, S, et al.
Published: (2018)

Immunogenicity of fractional doses of tetravalent a/c/y/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda
by: Guerin, P, et al.
Published: (2008)

Development of a live attenuated vaccine against fowl adenovirus by mutating fiber gene using crispr –CAS9 technology
by: Salisu, Ahmed
Published: (2020)

Induction of cell cycle and NK cell responses by live-attenuated oral vaccines against typhoid fever
by: Blohmke, CJ, et al.
Published: (2017)

Construction and characterization of recombinant MTBVAC. HIV, a new live attenuated vaccine against HIV and tuberculosis
by: Saubi, N, et al.
Published: (2018)

Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study
by: Turner, PJ, et al.
Published: (2015)

Early mucosal events promote distinct mucosal and systemic antibody responses to live attenuated influenza vaccine
by: Thwaites, RS, et al.
Published: (2023)